The EDGE

Diffuse large B-cell lymphoma: is salvage possible after failure of second-line treatment?

A Bazarbachi

Bone Marrow Transplant 2016 51: 1; advance online publication, October 5, 2015; 10.1038/bmt.2015.225

Reviews

Minimal residual disease testing after stem cell transplantation for multiple myeloma

A M Sherrod, P Hari, C A Mosse, R C Walker and R F Cornell

Bone Marrow Transplant 2016 51: 2-12; advance online publication, July 20, 2015; 10.1038/bmt.2015.164

Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients

C Fiuza-Luces, R J Simpson, M Ramírez, A Lucia and N A Berger

Bone Marrow Transplant 2016 51: 13-26; advance online publication, September 14, 2015; 10.1038/bmt.2015.195

Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients

M S Cairo, N Tarek, D A Lee and C Delaney

Bone Marrow Transplant 2016 51: 27-33; advance online publication, September 14, 2015; 10.1038/bmt.2015.196

Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology

M J Rioth, J Warner, B N Savani and M Jagasia

Bone Marrow Transplant 2016 51: 34-40; advance online publication, September 14, 2015; 10.1038/bmt.2015.210

Commentary

‘Coming of Age’ of artificial intelligence: evolution of survivorship care through information technology

S Hashmi

Bone Marrow Transplant 2016 51: 41-42; advance online publication, November 9, 2015; 10.1038/bmt.2015.271

Original Articles

ACUTE LEUKEMIA

Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT

S Nishiwaki, K Imai, S Mizuta, H Kanamori, K Ohashi, T Fukuda, Y Onishi, S Takahashi, N Uchida, T Eto, H Nakamae, T Yujiri, S Mori, T Nagamura-Inoue, R Suzuki, Y Atsuta and J Tanaka for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

Bone Marrow Transplant 2016 51: 43-50; advance online publication, September 21, 2015; 10.1038/bmt.2015.217

LYMPHOMA

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, N Milpied, J Radford, N Ketterer, O Shpilberg, U Dührsen, D Ma, J Brière, C Thieblemont, G Salles, C H Moskowitz, B Glass and C Gisselbrecht

Bone Marrow Transplant 2016 51: 51-57; advance online publication, September 14, 2015; 10.1038/bmt.2015.213

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

E Klyuchnikov, U Bacher, K Woo Ahn, J Carreras, N M Kröger, P N Hari, G H Ku, E Ayala, A I Chen, Y-B Chen, J B Cohen, C O Freytes, R P Gale, R T Kamble, M A Kharfan-Dabaja, H M Lazarus, R Martino, A Mussetti, B N Savani, H C Schouten, S Z Usmani, P H Wiernik, B Wirk, S M Smith, A Sureda and M Hamadani

Bone Marrow Transplant 2016 51: 58-66; advance online publication, October 5, 2015; 10.1038/bmt.2015.223

PLASMA CELL DISORDERS

A randomized study of melphalan 200 mg/m² vs 280 mg/m² as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

W I Bensinger, P S Becker, T A Gooley, T R Chauncey, D G Maloney, A K Gopal, D J Green, O W Press, M Lill, J J Ifthikharuddin, R Vescio, L A Holmberg and G L Phillips

Bone Marrow Transplant 2016 51: 67-71; advance online publication, September 14, 2015; 10.1038/bmt.2015.211

CONDITIONING

Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children

M Philippe, S Goutelle, J Guitton, X Fonrose, C Bergeron, P Girard, Y Bertrand and N Bleyzac

Bone Marrow Transplant 2016 51: 72-78; advance online publication, September 21, 2015; 10.1038/bmt.2015.218

HISTOCOMPATIBILITY AND DONOR SELECTION ISSUES

UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

N Santos, R Rodríguez-Romanos, J B Nieto, I Buño, C Vallejo, A Jiménez-Velasco, S Brunet, E Buces, J López-Jiménez, M González, C Ferrá, A Sampol, R de la Cámara, C Martínez and D Gallardo on behalf of the GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH)

Bone Marrow Transplant 2016 51: 79-82; advance online publication, September 14, 2015; 10.1038/bmt.2015.207

TRANSPLANT TOXICITIES

Survival of patients who develop solid tumors following hematopoietic stem cell transplantation

M J Ehrhardt, R Brazauskas, W He, J D Rizzo and B E Shaw

Bone Marrow Transplant 2016 51: 83-88; advance online publication, September 14, 2015; 10.1038/bmt.2015.203

Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

N Jaekel, K Lieder, S Albrecht, O Leismann, K Hubert, G Bug, N Kröger, U Platzbecker, M Stadler, K de Haas, S Altamura, M U Muckenthaler, D Niederwieser and H K Al-Ali

Bone Marrow Transplant 2016 51: 89-95; advance online publication, September 14, 2015; 10.1038/bmt.2015.204

GRAFT-VERSUS-HOST DISEASE

Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation

Y Arai, J Kanda, H Nakasone, T Kondo, N Uchida, T Fukuda, K Ohashi, K Kaida, K Iwato, T Eto, Y Kanda, H Nakamae, T Nagamura-Inoue, Y Morishima, M Hirokawa, Y Atsuta and M Murata on behalf of the GVHD working group of the Japan Society for Hematopoietic Cell Transplantation

Bone Marrow Transplant 2016 51: 96-102; advance online publication, September 14, 2015; 10.1038/bmt.2015.205

A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation

Y Kanda, T Kobayashi, T Mori, M Tanaka, C Nakaseko, A Yokota, R Watanabe, S Kako, K Kakihana, J Kato, A Tanihara, N Doki, M Ashizawa, S-i Kimura, M Kikuchi, H Kanamori and S Okamoto for the Kanto Study Group for Cell Therapy

Bone Marrow Transplant 2016 51: 103-109; advance online publication, October 5, 2015; 10.1038/bmt.2015.222

IMMUNE RECOVERY

High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT OPEN

R D Danby, W Zhang, P Medd, T J Littlewood, A Peniket, V Rocha and D J Roberts

Bone Marrow Transplant 2016 51: 110-118; advance online publication, September 21, 2015; 10.1038/bmt.2015.215

INFECTIONS

Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus

M Boukhvalova, J C G Blanco, A R Falsey and J Mond

Bone Marrow Transplant 2016 51: 119-126; advance online publication, September 14, 2015; 10.1038/bmt.2015.212

Technical Report

Cerebrospinal fluid chimerism analysis in patients with neurological symptoms after allogeneic cell transplantation

M Waterhouse, I Bartsch, H Bertz, J Duyster and J Finke

Bone Marrow Transplant 2016 51: 127-131; advance online publication, October 5, 2015; 10.1038/bmt.2015.226

Letters To The Editor

Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation

L Haïk, M Beylot-Barry, S Vigouroux, R Tabrizi and N Milpied

Bone Marrow Transplant 2016 51: 132-133; advance online publication, September 14, 2015; 10.1038/bmt.2015.198

Use of bone marrow-derived cells for regenerative medicine in Cuba

P Hernández

Bone Marrow Transplant 2016 51: 134; advance online publication, September 14, 2015; 10.1038/bmt.2015.200

Anicteric veno-occlusive disease after hematopoietic stem cell transplantation in children

J C Naples, M A Skeens, J Auletta, H Rangarajan, R Abu-Arja, E Horwitz, J Stanek and R S Bajwa

Bone Marrow Transplant 2016 51: 135-137; advance online publication, September 14, 2015; 10.1038/bmt.2015.208

Host immunity dictates influenza A(H1N1)pdm09 infection outcome in hematology–oncology patients

J Gooskens, W A F Marijt, E H R van Essen, G F Rimmelzwaan and A C M Kroes

Bone Marrow Transplant 2016 51: 138-141; advance online publication, September 21, 2015; 10.1038/bmt.2015.214

Urinary-derived human chorionic gonadotropin to induce tolerance and promote healing in steroid-refractory GvHD

S G Holtan and A Panoskaltsis-Mortari

Bone Marrow Transplant 2016 51: 142-143; advance online publication, September 21, 2015; 10.1038/bmt.2015.220

The impact of pre-transplant body weight on short- and long-term outcomes after allogeneic hematopoietic cell transplantation in adults using different weight classification tools

P Urbain, G Ihorst, J Finke and H Bertz

Bone Marrow Transplant 2016 51: 144-147; advance online publication, October 5, 2015; 10.1038/bmt.2015.219

Clinically significant adverse events after major ABO mismatch BMT

R S Nickel, E K Waller, M Qayed and K-Y Chiang

Bone Marrow Transplant 2016 51: 148-149; advance online publication, October 5, 2015; 10.1038/bmt.2015.230

Early post-transplant contrast-enhanced abdominopelvic CT scan predicts the risk of subsequent acute GvHD

A Rashidi, M F Lin and A F Cashen

Bone Marrow Transplant 2016 51: 150-152; advance online publication, October 5, 2015; 10.1038/bmt.2015.232

Physician-diagnosed depression and suicides in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up

P A Hoffmeister, B E Storer, K L Syrjala and K S Baker

Bone Marrow Transplant 2016 51: 153-156; advance online publication, October 5, 2015; 10.1038/bmt.2015.233

Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged >55 years with hematological malignancies

K Miyao, M Sawa, Y Kuwatsuka, Y Ozawa, T Kato, A Kohno, H Sao, T Nishida, H Iida, K Naito, H Tsurumi, H Taji, S Mizuta, S Kusumoto, K Nakase, Y Morishita, N Kawashima, K Miyamura and M Murata for the Nagoya Blood and Marrow Transplantation Group

Bone Marrow Transplant 2016 51: 157-160; advance online publication, October 5, 2015; 10.1038/bmt.2015.235